The development of diffuse large B-cell lymphoma (DLBCL) in patients with a history of classical Hodgkin lymphoma (cHL) is a well-established but rarely documented event, particularly when it originates from the mixed cellularity subtype, an occurrence that has been minimally reported and documented.We present the case of a 47-year-old woman with mixed cellularity classical Hodgkin lymphoma (MC-cHL), Lugano stage IV, who underwent hematopoietic cell transplantation, subsequently relapsed, and later developed DLBCL, raising the possibility of histologic transformation.She was treated with polatuzumab vedotin, rituximab, and ibrutinib.
No takes yet. Share an insight, caveat, or question.
Navarro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: